Fractyl Health (GUTS) vs SiNtx Technologies (SINT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
SiNtx Technologies (SINT) has outperformed Fractyl Health (GUTS) over the past year, losing 65.7% versus a loss of 95.1%. Fractyl Health is the larger company by market cap ($10.9 million vs $8.3 million), about 1.3 times the size, while SiNtx Technologies is growing revenue faster (-64.7% vs -100.0%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GUTS | SINT |
|---|---|---|
| Share price | $0.82 | $1.10 |
| Market cap | $10.88M | $8.31M |
| 1-day change | -14.16% | -8.74% |
| YTD return | -96.89% | -71.50% |
| 1-year return | -95.12% | -65.73% |
| 5-year return | — | -99.99% |
| EPS (TTM) | $-3.14 | $-1.54 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $1.02M |
| Revenue growth (YoY) | -100.00% | -64.74% |
| Net income (latest FY) | $-140.95M | $-10.36M |
| Gross margin | — | 45.28% |
| Operating margin | — | -1053.14% |
| Net margin | — | -1018.07% |
| 52-week high | $29.34 | $4.46 |
| 52-week low | $0.784 | $1.09 |
| Distance from 52-week high | -97.21% | -75.34% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +7265.85% | +740.91% |
| Average volume | 504.39K | 48.13K |
| Shares outstanding | 13.26M | 7.56M |
| Employees | 100 | 32 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SINT has outperformed GUTS by 29.4 percentage points over the past year.
- SiNtx Technologies grew revenue faster in its latest fiscal year (-64.74% vs -100.00%).
About Fractyl Health
GUTS stock →Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
Health Care · Medical/Dental Instruments · 100 employees
About SiNtx Technologies
SINT stock →Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. The company offers monolithic solid silicon nitride; solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyether ether ketone, and Polyether Ether Ketone (PEE).
Health Care · Medical/Dental Instruments · 32 employees
GUTS vs SINT FAQ
Which is bigger, Fractyl Health or SiNtx Technologies?
Fractyl Health (GUTS) is larger, with a market capitalization of $10.88M compared with $8.31M for SiNtx Technologies (SINT).
Which stock has performed better over the past year, GUTS or SINT?
SINT returned -65.73% over the past 12 months, compared with -95.12% for GUTS (price return, excluding dividends). Past performance does not predict future results.
Are Fractyl Health and SiNtx Technologies in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.